Welcome to our dedicated page for Boston Scien Cp news (Ticker: BSX), a resource for investors and traders seeking the latest updates and insights on Boston Scien Cp stock.
Boston Scientific Corporation (BSX) delivers innovative medical solutions through advanced devices for cardiovascular care, neuromodulation, and minimally invasive procedures. This news hub provides investors and healthcare professionals with timely updates on regulatory milestones, product innovations, and strategic initiatives shaping the future of patient care.
Access official press releases covering clinical trial results, FDA clearances, and financial performance alongside analysis of emerging trends in interventional therapies. Our curated collection includes updates on electrophysiology advancements, urological device developments, and global healthcare partnerships.
Key updates feature Boston Scientific's leadership in catheter-based technologies, progress in chronic pain management solutions, and expansions in diagnostic imaging capabilities. Stay informed about acquisitions, research collaborations, and quality improvement initiatives that reinforce the company's market position.
Bookmark this page for direct access to verified information about BSX's contributions to interventional cardiology and operational developments. Regularly updated to serve as your primary resource for understanding Boston Scientific's impact on modern healthcare delivery.
Boston Scientific Corporation reported net sales of $3.389 billion for Q1 2023, a rise of 12.0% year-over-year, exceeding guidance of 3-5%. The company achieved a GAAP net income of $300 million or $0.21 per share, up from $97 million or $0.07 per share in the prior year. Adjusted EPS was $0.47, surpassing guidance of $0.42 to $0.44. Key growth areas included U.S. sales with a 12.7% increase, and 20.2% growth in emerging markets. The company introduced several innovative medical devices, including the LithoVue™ Elite and POLARx™ FIT systems. Full-year sales growth is projected at 8.5% to 10.5%, with adjusted EPS expected between $1.90 to $1.96. A conference call will provide further insights.
FAQ
What is the current stock price of Boston Scien Cp (BSX)?
What is the market cap of Boston Scien Cp (BSX)?
